TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02960451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRIME care
Description: Specialist medication, cognitive behavior therapy, family-focused therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Medication and psychotherapy as available form community providers
Study: NCT01551173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin sodium
Description: Fluvastatin sodium Extended Release Tablets 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin sodium
Description: Fluvastatin sodium Extended Release Tablets 80mg
Study: NCT06254339

Intervention type: PROCEDURE
Intervention: OAGB
Description: using OAGB procedure as metabolic bariatric surgery

Intervention type: PROCEDURE
Intervention: DJB-SG
Description: using DJB-SG procedure as metabolic bariatric surgery
Study: NCT00327093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: indication : second intention treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Indication: first intention treatment
Study: NCT04612400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral amino acid tracer
Description: Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral amino acid tracer
Description: Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
Study: NCT04617951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ishige Okamurae extracts group
Description: Ishige Okamurae extracts 300 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 300 mg/day for 12 weeks
Study: NCT01694238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate incision
Study: NCT00706251

Intervention type: DEVICE
Intervention: Silicone tube
Description: Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
Study: NCT03529266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Porcine Fibrin Sealant (PFS)
Description: 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
Study: NCT01694238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circular incision

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesh enforced cruciate incision
Study: NCT03346343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive forced airway oscillometry
Description: This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
Study: NCT01754649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
Study: NCT03210766

Intervention type: DRUG
Intervention: Nabilone

Intervention type: DRUG
Intervention: THC/CBD
Study: NCT03870490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133 + cefepime
Description: IV infusion (3 doses)
Study: NCT02098772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Study: NCT00457353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Clausii
Description: For 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral rehydration therapy
Description: For 5 days
Study: NCT03529266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
Study: NCT00751777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heat-labile enterotoxin of E. coli (LT)
Description: Travelers' Diarrhea Vaccine System
Study: NCT02105090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Local

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Local
Study: NCT00751777

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Travelers' Diarrhea Vaccine System
Study: NCT02105090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Study: NCT04568109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Description: The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
Study: NCT01156584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511 vector
Description: Single, stereotactic, transcranial, intratumoral injection or intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: 4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
Study: NCT00657605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin
Description: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
Study: NCT02273947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose by mouth for each treatment specified
Study: NCT02607072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)/aspirin 200 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)/aspirin 100 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03884764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency
Description: patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ganglion impar denervation
Description: patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
Study: NCT01314729

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiber-reinforced-composite retainer
Description: this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Composite-wire retainer
Description: this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
Study: NCT03406663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change, \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Fasting SMPG (median of the last 3 days including current day) in the range of~* 7.8 mmol/L, increase 6 units of Gla-300 dose, \> 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change,~* 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose, \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator
Study: NCT04155749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anitocabtagene-autoleucel
Description: Chimeric Antigen Receptor T cells
Study: NCT02290184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PilAm Go4Health Weight-loss Program
Description: This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
Study: NCT05968235

Intervention type: OTHER
Intervention: Collecting blood samples
Description: Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.

Intervention type: OTHER
Intervention: Collecting blood samples
Description: Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
Study: NCT03426904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFOX
Description: 4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional adjuvant FOLFOX
Description: 12 cycles of postoperative FOLFOX chemotherapy
Study: NCT04103008

Intervention type: DIAGNOSTIC_TEST
Intervention: Speckle tracking echocardiography
Description: assess left ventricular function on admission and after 40 days

Intervention type: DIAGNOSTIC_TEST
Intervention: Speckle tracking echocardiography
Description: assess left ventricular function on admission and after 40 days
Study: NCT01692574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification for Weight Loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Modification for Weight Loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Approach to Weight Loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy for Depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavior Therapy for Depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression Support and Education
Study: NCT00633659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 mL of Hemospan (MP4OX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voluven (HES 130/0.4)
Description: 250 mL of Voluven (HES 130/0.4) solution
Study: NCT00724945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: multifocal contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: multifocal contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: multifocal contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: multifocal contact lens
Study: NCT04161196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsil pillars suturing
Description: The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tonsillectomy without tonsil pillars suturing
Description: tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
Study: NCT02402062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 + Sunitinib
Description: Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.
Study: NCT01577914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Tablets USP 12.5 mg
Description: 12.5mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 12.5mg tablet once a day
Study: NCT04128995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Medical Therapy and Bariatric Surgery
Description: Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Medical Therapy
Description: Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric Surgery
Description: Vertical Sleeve Gastrectomy for youth without type 2 diabetes
Study: NCT01994031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Study: NCT02213783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
Study: NCT03994939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together (FTT)
Description: FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
Study: NCT01531920

Intervention type: DRUG
Group type: OTHER
Intervention: alcohol + placebo
Description: Part A alcohol + placebo

Intervention type: DRUG
Group type: OTHER
Intervention: alcohol + perampanel
Description: Part A: alcohol + perampanel

Intervention type: DRUG
Group type: OTHER
Intervention: perampanel + alcohol
Description: Part B: perampanel + alcohol

Intervention type: DRUG
Group type: OTHER
Intervention: placebo + alcohol
Description: Part B: placebo + alcohol
Study: NCT01066364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam Hcl
Description: 3.75 gm/day (six 675 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colesevelam Hcl
Description: 3.75 gm/day (six 675 mg tablets)
Study: NCT02079571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut water
Description: 250 ml Coconut water for each subject

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger tea
Description: 250 ml for each subject
Study: NCT01203384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5074 1x
Description: oral tablet, 1x, once a day in the morning for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5074 2x
Description: oral tablet, 2x, once a day in the morning for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5074 3x
Description: oral tablet, 3x, once a day in the morning for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, placebo, once a day in the morning for 14 days
Study: NCT02834468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX Combined With RTX, CSA and IVIG
Description: The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
Study: NCT03740750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermacare heat wraps
Description: low level continuous heat wrap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermacare heat wraps
Description: low level continuous heat wrap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermacare heat wraps
Description: low level continuous heat wrap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham heat
Description: expended heat wrap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham heat
Description: expended heat wrap

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham heat
Description: expended heat wrap

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Tens
Description: tens applied but unit not turned on

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Tens
Description: tens applied but unit not turned on